NAGESHWARA V. DASARI to Neuroendocrine Tumors
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Neuroendocrine Tumors.
Connection Strength
1.155
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
Score: 0.549
-
Initial treatment of well-differentiated neuroendocrine tumors. Oncology (Williston Park). 2014 Nov; 28(11):945-7.
Score: 0.305
-
Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park). 2014 Sep; 28(9):762-3.
Score: 0.302